ChromaDex (NASDAQ:CDXC) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of ChromaDex (NASDAQ:CDXC) in a research report issued to clients and investors on Saturday. The brokerage set a “buy” rating on the stock.

CDXC has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of ChromaDex in a report on Monday, March 17th. LADENBURG THALM/SH SH increased their price objective on shares of ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research note on Wednesday, March 5th.

ChromaDex Price Performance

The company has a market capitalization of $611.50 million, a P/E ratio of 787.29 and a beta of 2.21. The stock’s 50-day moving average is $6.16 and its two-hundred day moving average is $5.44. ChromaDex has a 1-year low of $2.31 and a 1-year high of $9.18.

Institutional Investors Weigh In On ChromaDex

Several large investors have recently made changes to their positions in the business. Barclays PLC increased its holdings in ChromaDex by 322.1% during the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after buying an additional 53,472 shares during the last quarter. Sargent Investment Group LLC purchased a new stake in shares of ChromaDex during the 4th quarter worth approximately $263,000. JPMorgan Chase & Co. raised its holdings in shares of ChromaDex by 11.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after purchasing an additional 33,150 shares during the period. FMR LLC purchased a new position in ChromaDex in the third quarter valued at approximately $55,000. Finally, State Street Corp lifted its stake in ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares during the last quarter. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.